Doing Life Sciences Deals in 2024

Nearly one hundred life sciences professionals convened at Mintz’s Boston office last week for an event we hosted in partnership with the LES (Licensing Executives Society). I moderated a panel, “Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale,” with business development leaders from GSK, Johnson & Johnson, Locust Walk, and Astria Therapeutics. We were fortunate to have a mix of expert perspectives at the table, representing large pharmaceutical companies, investors,…
By: Mintz
Previous Story

USPTO Issues Guidance on AI Use to Patent Professionals — AI: The Washington Report

Next Story

A crafty new Android notification power-up